Please assess the completion status of the following clinical trial:

Trial Title: Effect of Terlipressin Infusion on Systemic and Hepatic Hemodynamics During Hepatobiliary Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years.~* Any gender.~* ASA (American Society of Anesthesiologists) Classification( Class I-II)~* Patients undergoing major elective hepatobiliary surgery.~Exclusion Criteria:~* Preoperative renal failure (GFR \< 50 ml/min).~* Severe liver dysfunction (Child- turcotte -Pugh grade C).~* Hyponatremia (\<132 mmol/l).~* Severe aortic regurgitation, severe mitral regurgitation, heart failure.~* Symptomatic coronary heart disease.~* Bradycardic arrhythmia (heart rate \< 60/min).~* Peripheral artery occlusive disease (clinical stadium II-IV).~* Uncontrolled arterial hypertension (Blood pressure \>160/100 mmHg despite intensive treatment).~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Terlipressin (Type: ACTIVE_COMPARATOR): Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
- CONTROL (Type: PLACEBO_COMPARATOR): Patients receive the same volume of 0.9% saline in place of terlipressin for the same duration(50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).